An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

Status unconfirmed · Phase 2

Conditions studied: Dyslipidemia

In brief

The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.

Key facts

Study ID

NCT02052986

Run by

New York Hospital Queens

People needed

100

Last updated by the study team

2014-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects (> or = 18 years of age)
• Enrolled in Cardiac Rehabilitation clinic with documented cardiovascular disease as assessed by the principle investigator
• Has had cardiovascular examination within the past 2 months

You may not qualify if…

• Subjects who refuse to provide written consent
• Subjects with medical conditions, as determined by the principal investigator, which prevented them from study participation
• Subjects with a known bleeding or clotting disorder
• Subjects with known allergies to fish
• Subjects with an implantable cardiac defibrillator
• Subjects with a heart transplant
• Female subjects who are currently taking hormone replacement therapy
• Subjects who are pregnant or planning on becoming pregnant
• Subjects currently taking Omega-3 fatty acid supplements (either under medical supervision or self-administered)

Where it is running

• The NYHQ Cardiac Health Center — Fresh Meadows, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.